News

Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.

Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.

Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences...

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.

AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.

AstraZeneca and Ionis Pharmaceuticals shares are down roughly 8% and 20%, respectively, after the drugmakers said their heart therapy Wainua failed in a late-stage trial. The companies pointed to a smaller group of patients in the trial to show some potential for the drug: Patients who weren’t already taking either Pfizer or BridgeBio’s drug for this condition saw a relative risk reduction in major heart problems or deaths.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

Things are going from bad to worse for the pharmaceutical giant.

Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...

In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.

The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.

(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a

Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to standard chemotherapy docetaxel in patients with metastatic non squamous non small cell lung cancer. The drug, part of the Seagen portfolio acquired for US$43b, showed a manageable safety profile and encouraging signals in a subset of patients, but the main efficacy goal was not met. For Pfizer,...

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

In a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.

A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks under $30 often get dismissed as broken or speculative, but a handful of large, cash-generative businesses currently trade in that zone with the ... Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.